Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Eye (Lond). 2021 Jul;35(7):1946-1953. doi: 10.1038/s41433-020-01198-y. Epub 2020 Sep 29.
To investigate the clinical features, prognostic outcomes of patients with orbital and ocular adnexal lymphoma (OALs) in Taiwanese cohort.
Total 112 patients with OALs were retrospectively reviewed. Demographic information such as age, gender, lymphoma subtype, tumor location and treatment modalities were recorded. The primary endpoints were disease-specific survival (DSS), and progression-free survival (PFS).
The mean patient age was 59.0 ± 15.5 years (range, 23-92 years). The major histopathologic subtypes were mucosa-associated lymphoid tissue (MALT) lymphoma in 76 patients (67.9%), followed by diffuse large B-cell lymphoma (DLBCL) (9.8%), follicular cell lymphoma (FL) (8.0%), and small lymphocytic lymphoma (SLL) (5.4%). The anatomical locations for OALs were the orbit (44 patients, 39.3%), the conjunctiva (31 patients, 27.7%), the lacrimal gland (28 patients, 25.0%), and the eyelid (8 patients, 7.1%). With a mean follow-up time of 74.5 ± 59.8 months (range 6-342 months), the DSS for all patients were 93.1%, 87.7%, and 68.8% at 60, 120, and 180 months' follow-up, respectively. The PFS at 60, 120, and 180 months' follow-up were 86.2%, 61.2%, and 44.6%, respectively. Regarding the analysis of prognostic factors, patients with high grade lymphoma subtype and advanced stage exhibited a worse prognosis.
MALT type lymphoma constitutes most of OALs in Taiwan and occurs more frequently than in Western countries. Patients with MALT lymphoma, FL, SLL and earlier stage have favorable outcomes compared with patients of high grade lymphoma and Ann Arbor stage IV lymphoma.
研究台湾眼眶和眼附属器淋巴瘤（OAL）患者的临床特征和预后结果。
回顾性分析了 112 例 OAL 患者。记录了患者的年龄、性别、淋巴瘤亚型、肿瘤部位和治疗方式等人口统计学信息。主要终点为疾病特异性生存（DSS）和无进展生存（PFS）。
患者的平均年龄为 59.0±15.5 岁（范围为 23-92 岁）。主要组织病理学亚型为黏膜相关淋巴组织（MALT）淋巴瘤 76 例（67.9%），其次为弥漫性大 B 细胞淋巴瘤（DLBCL）9.8%、滤泡细胞淋巴瘤（FL）8.0%和小淋巴细胞淋巴瘤（SLL）5.4%。OAL 的解剖位置为眼眶（44 例，39.3%）、结膜（31 例，27.7%）、泪腺（28 例，25.0%）和眼睑（8 例，7.1%）。中位随访时间为 74.5±59.8 个月（范围为 6-342 个月），所有患者的 DSS 在 60、120 和 180 个月的随访中分别为 93.1%、87.7%和 68.8%。PFS 在 60、120 和 180 个月的随访中分别为 86.2%、61.2%和 44.6%。关于预后因素的分析，高级别淋巴瘤亚型和晚期患者的预后较差。
MALT 型淋巴瘤构成了台湾 OAL 的大多数，其发生率高于西方国家。与高级别淋巴瘤和 Ann Arbor 分期 IV 淋巴瘤患者相比，MALT 淋巴瘤、FL、SLL 和早期患者的预后较好。
